Information  X 
Enter a valid email address

Kanabo Group PLC (KNB)

  Print      Mail a friend

Tuesday 23 March, 2021

Kanabo Group PLC

Publication of Research Note

RNS Number : 1700T
Kanabo Group PLC
23 March 2021

23 March 2021


Kanabo Group Plc

"Kanabo" or the "Company"



Kanabo Group Plc (LSE: KNB), a medical cannabis R&D Company that focuses on the distribution of cannabis-derived products for medical patients, and non-THC products for CBD consumers, welcomes the publication of an analyst report by Equity Development Limited, an experienced investment research and advisory company.


A copy of the report is available at:


For more information, please contact:


Kanabo Group +972 523173633

Meirav Horn, CFO


Peterhouse Capital Limited +44 (0)20 7469 0930

Eran Zucker / Lucy Williams / Allie Feuerlein



Kanabo aims to create a new standard in the medical cannabis industry by building an ecosystem that improves the well-being of millions around the world by providing an alternative solution to the smoking of medicinal cannabis flowers. With a focus on the distribution of cannabis-derived products for medical patients, and non-THC products for CBD consumers, Kanabo has conducted extensive Research & Development in order to produce high-quality cannabis extract formulas, innovative medical-grade vaporizers, and various non-smoking consumption solutions.


This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

a d v e r t i s e m e n t